首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 265 毫秒
1.
BACKGROUND: Recently the potential of myocardial repair by transplantation of autologous bone marrow stem cells has been suggested. Whether the additional intracoronary transplantation of autologous peripheral blood stem cells (PBSC), which were mobilized by granulocyte-colony-stimulating factor (G-CSF), could safely improve myocardial function in patients with acute myocardial infarction (AMI) was investigated. METHODS AND RESULTS: Seventy-three patients with AMI who had successfully undergone percutaneous coronary intervention (PCI) were enrolled in the present prospective nonrandomized open-labeled study. Ten patients with elective PCI received G-CSF for 4 days followed by intracoronary PBSC transplantation. Thirty-two patients with primary PCI and 31 patients with recent AMI and elective PCI served as controls. The left ventricular (LV) function was evaluated using echocardiography and magnetic resonance imaging. G-CSF and intracoronary transplantation of PBSC did not incur any periprocedural myocardial damage. After 6 months, the LV ejection fraction was significantly improved in the cell therapy group. For 2 years of the follow-up period, there was no adverse clinical events, except one asymptomatic in-stent restenosis. However, comparable improvement of the LV ejection fraction was also identified in the primary PCI and elective PCI control groups. CONCLUSIONS: In the present study, additional intracoronary infusion of PBSC was safe and feasible for the patients with AMI who had undergone PCI, but did not lead to a significant improvement in LV function compared to standard reperfusion treatment.  相似文献   

2.
急性心肌梗死后延迟冠状动脉介入治疗的疗效   总被引:2,自引:0,他引:2  
目的评价急性心肌梗死(acute myocardial infarction,AMI)后进行延迟经皮冠状动脉介入治疗(delayed percutaneous coronary intervention,dPCI)对心肌梗死患者的治疗效果。方法dPCI组选择ST段抬高的AMI56例,各例于发病后7~14d实施dPCI,对照组为同期入院而未进行PCI治疗的ST段抬高的AMI47例。两组均常规应用药物治疗。观察住院期间和随访6个月时的主要心血管事件和超声心动图的变化。结果6个月时dPCI组左心室舒张末容积指数(left ventricular end-diastolic volumeindex,LVEDVI)、左心室收缩末期容积指数(left ventricular end-systolic volume index,LVESVI)及左心室射血分数(left ventricular ejection fraction,LVEF)、左心室室壁节段运动评分指数(left ventricular wall motion score index,WMSI)及异常室壁节段恢复率优于对照组,dPCI组总临床事件发生率低于对照组,差异有统计学意义(P<0.05)。结论dPCI可有效抑制左心室重构和改善左心室功能,可能有利于减少远期心力衰竭的发生。  相似文献   

3.
目的 :评价心肌梗死并左心功能不全患者经皮冠状动脉介入 (PCI)治疗对左心收缩功能和左心室重构的影响。方法 :急性心肌梗死 (AMI)患者 30例 ,陈旧性心肌梗死 (OMI) 2 2例 ,经 PTCA、支架术治疗 ,术后随访 3个月 ,超声心动图测定左室舒张末内径 (L VEd)、左心房内径 (L Ad)、左室舒张末容积 (L VEDV)、左室收缩末容积(L VESV)、左室射血分数 (L VEF)和左室短轴缩短率 (L VFS) ,比较治疗前后各参数的变化。结果 :PCI治疗后L VEd、L Ad、L VEDV、L VESV显著减少 (P<0 .0 1)、L VEF和 L VFS显著增高 (P<0 .0 1) ,尤以 AMI组明显 ,并且冠状动脉血运重建的时间越早 ,心功能恢复越好。结论 :心肌梗死并左心功能不全患者尽早 PCI治疗可明显改善左心室收缩功能 ,可部份阻抑左心室重构。  相似文献   

4.
心肌梗死并心功能不全患者冠状动脉介入治疗的作用   总被引:2,自引:1,他引:2  
目的 :评价心肌梗死 (MI)并左心功能不全患者经皮冠状动脉介入术 (PCI)对左心收缩功能和左心室重构的作用。方法 :5 2例MI并左心功能不全患者 ,急性心肌梗死 (AMI) 30例 ,陈旧性心肌梗死 (OMI) 2 2例 ,行经皮腔内冠状动脉成形术加支架术治疗 ,术后随访 3个月 ,超声心动图测定左室舒张末内径 (LVEd)、左心房内径(LAd)、左室舒张末容积 (LVEDV)、左室收缩末容积 (LVESV)、左室射血分数 (LVEF)和左室短轴缩短率 (LVFS) ,比较治疗前后各参数的变化。结果 :PCI治疗后LVEd、LAd、LVEDV、LVESV较治疗前均明显减少 (均P <0 .0 1)、LVEF和LVFS明显增高 (P <0 .0 1) ,尤以AMI组明显 ,并且冠状动脉血运重建的时间越早 ,心功能恢复越好。结论 :MI并左心功能不全患者尽早PCI治疗可明显改善左心室收缩功能 ,部分阻抑左心室重构。  相似文献   

5.
目的:探讨乌拉地尔对急性心肌梗死(AMI)急诊经皮冠状动脉介入治疗(PCI)患者心肌灌注和心功能的影响。方法:对经急诊PCI治疗的AMI患者54例,随机分为乌拉地尔组、硝酸甘油组和对照组。分别于经皮腔内冠状动脉成形术前冠状动脉内注射乌拉地尔、硝酸甘油、生理盐水。观察PCI术前、术后心肌梗死溶栓试验(TIMI)血流、校正的TIMI帧计数(cTFC)、心肌充血分级(MBG)、ST段回落、心肌坏死指标、左心室射血分数(LVEF)及住院期间主要心血管不良事件(MACE)。结果:乌拉地尔组与硝酸甘油组和对照组相比,PCI后cTFC降低、MBG增加、ST段回落增加、LVEF增加、CK和TnT峰值降低(P均<0.01)。结论:乌拉地尔可改善AMI急诊PCI患者冠状动脉血流、心肌灌注和左心室收缩功能,减少梗死面积,不增加住院期间MACE。  相似文献   

6.
目的:研究芪参益气滴丸对经皮冠脉介入治疗术(PCI)后急性前壁心肌梗死(AMI)患者冠脉血流和左室功能的影响。方法选取符合要求的前壁 AMI患者83例,采用随机对照双盲的方法分为对照组和治疗组,对照组给予常规西药及 PCI治疗,治疗组在对照组用药及 PCI 治疗的基础上加用芪参益气滴丸。比较术后两组患者在冠脉血流和左室功能方面的差异。结果两组共失访3例,失访率3.61%。术后两组间冠脉 TIMI3级血流差异无统计学意义(P〉0.05);治疗9个月后治疗组在 TIMI3级血流、冠脉内再狭窄情况及侧支循环评分方面均优于对照组,差异有统计学意义(P〈0.05);超声心动图显示,PCI术后9个月,治疗组在左室射血分数(LVEF)、心搏出量(CO)、心脏指数(CI)和左室收缩末期容积(LVESV)方面明显优于对照组,差异有统计学意义(P〈0.05),尤其在 LVEF方面,呈稳步提高趋势。结论芪参益气滴丸对改善 PCI术后前壁 AMI患者冠脉血流和左室功能方面有积极影响。  相似文献   

7.
In this prospective randomized trial on patients with acute myocardial infarction (AMI) treated with primary percutaneous coronary intervention (PCI), we hypothesized that abciximab administered intracoronarily, downstream of the coronary occlusion, leads to a greater degree of myocardial salvage and better left ventricular function recovery compared with the usual abciximab administration. Forty-five consecutive patients with first AMI and infarct-related artery TIMI flow 0-1 undergoing primary PCI were enrolled. Twenty-two patients were randomly assigned to the intracoronary treatment and 23 to the usual treatment. The initial perfusion defect, final infarct size, myocardial salvage, salvage index, and left ventricular function recovery were assessed by serial scintigraphic scans performed at admission and 7 days and 1 month after PCI. Angiographic myocardial blush grade, corrected TIMI frame count, and electrocardiographic ST segment elevation reduction were also assessed as markers of myocardial reperfusion. Final infarct size was significantly smaller (P = 0.043) and salvage index significantly higher (P = 0.003) in the intracoronary treatment group as a result of a greater degree of myocardial salvage (P = 0.0001). The increase of left ventricular ejection fraction at 1 month was significantly higher in the intracoronary treatment patients (P = 0.013). The markers of myocardial reperfusion were also significantly better in the intracoronary treatment group. In patients with AMI and occluded infarct-related artery treated with primary PCI, intracoronary abciximab given just before PCI downstream of the occlusion is associated to a greater degree of myocardial salvage than the usual abciximab protocol. This benefit is mainly related to a substantial reduction in final infarct size, which leads to an improvement in left ventricular ejection fraction.  相似文献   

8.
刘胜强  娄闯  袁博  任晖 《心脏杂志》2015,27(4):437-439
目的 比较急诊与限期经皮冠脉介入(PCI)术对急性心肌梗死(AMI)后心率变异性(HRV)及心功能的影响。方法 共收集随访资料完整的120例AMI患者,包括行急诊PCI治疗42例和行限期PCI治疗38例;而未行任何冠脉再灌注治疗(包括静脉溶栓或PCI术)40例为对照组。分析比较3组患者AMI后1个月、6个月随访时动态心电图检查中的HRV资料及心脏超声检查测定的左室射血分数(LVEF)。结果 AMI后1、6个月时,与未行任何冠脉再灌注治疗的对照组患者相比较,PCI治疗组患者HRV时域指标SDNN、SDANN、rMSSD、PNN50及LVEF均显著提高,而且急诊PCI治疗组患者较限期PCI治疗组患者进一步提高,差异性均有统计学意义(P<0.05,P<0.01)。结论 急诊与限期PCI都可以改善提高AMI患者的HRV及心功能,尤以急诊PCI更为显著。  相似文献   

9.
目的 探讨不同时间段行经皮冠状动脉介入治疗(PCI)对急性心肌梗死(AMI)后左心室室壁瘤(LVA)形成的逆转效应及其对心功能的影响.方法 选择2001年1月至2004年7月我院收治的首次前壁AMI患者,经导管法左心室造影确定合并室壁瘤者共326例,根据AMI发病后行PCI的时间分为:发病≤3 h组、4~6 h组、7~12 h组和1周组(发病时间≥13 h且小于1周),4组患者于PCI后即行导管法左心室造影,测定心室容积、压力参数和室壁运动积分;PCI术后1周时行平衡法核素心室造影,测定反常室壁容积指数;6个月时重复上述检查,并随访3年,记录主要心脏事件(MACE)的发生率. 结果 PCI术后6个月随访,发病≤3 h组、4~6 h组、7~12 h组、1周组左心室舒张末期容积指数、左心室收缩末期容积指数、左心室室壁运动积分、左心室舒张末期压力均较行PCI时降低(均P<0.05),而左心室射血分数较前增高(P<0.05),其中发病≤3 h组变化最为显著.PCI术后6个月,发病≤3 h组反常室壁容积指数明显低于4~6 h组、7~12 h组、1周组,分别为:(12.1±2.1)%与(15.4±2.4)%、(16.5±2.5)%、(20.4±3.7)%,均P<0.05.住院期间及术后3年随访,≤3 h组、4~6 h组、7~12 h组3组MACE发病率低于1周组,3年随访时病死率均低于1周组(分别为2.8%、3.0%、3.1%与17.9%,均P<0.05). 结论 对AMI患者越早期开通梗死相关动脉,越能有效地抑制并逆转LVA的形成,提高左心室功能,改善患者的预后.  相似文献   

10.
目的 探讨急性ST段抬高心肌梗死急诊经皮冠状动脉介入治疗(PCI)中联合应用ZEEK血栓抽吸导管和替罗非班对心肌组织灌注及临床预后的影响.方法 84例经冠脉造影证实为血栓负荷病变的急性ST段抬高心肌梗死患者随机分为血栓抽吸+替罗非班42例(A组)和标准PCI 42例(B组),比较两组患者手术后即刻梗死相关动脉(IRA)的心肌梗死溶栓(TIMI)血流、心肌灌注分级(MBG)、心电图ST段回落百分比、左心室射血分数(LVEF)及住院期间主要心脏不良事件(MACE)和出血性并发症发生率.结果 A组术后即刻TIMI血流、MBG、ST段抬高回落百分比及LVEF均明显优于B组(P〈0.05),两组住院期间的MACE发生率及出血并发症比较差异无统计学意义(P〉0.05).结论 在急性心肌梗死急诊PCI中联合使用ZEEK导管血栓抽吸和替罗非班安全可行,可有效清除冠状动脉内血栓,改善心肌组织灌注和术后心脏功能,并且不增加主要心脏不良事件的发生率.  相似文献   

11.
陈玉善  张燕  李靖 《中国心血管杂志》2007,12(6):424-426,433
目的评价经皮冠状动脉介入治疗(PCI)对伴左心室收缩功能不全的冠状动脉慢性完全闭塞(CTO)患者左室重构及心功能的影响。方法选择该院心内科住院患者88例,经冠状动脉造影(CAG)证实均为伴左心室收缩功能不全的慢性冠状动脉闭塞病变,根据是否对CTO病变行PCI治疗,将患者分为PCI治疗组(n=48)和药物治疗组(n=40)。于CAG术前及术后1周、3个月、6个月分别进行超声心动图检查,计算校正的舒张末期容积指数(LVEDVI)、收缩末期容积指数(LVESVI)和左室射血分数(LVEF),比较两组患者左室重构及心功能的差异。结果两组CAG基线资料比较,差异无统计学意义。CAG术后1周时两组LVEDVI、LVESVI、LVEF比较,差异无统计学意义。3个月时PCI组LVEDVI较术前显著降低,LVEF显著提高;与药物治疗组相比,差异也有统计学意义。6个月时PCI组LVEDVI进一步降低,LVEF进一步提高。结论PCI能够改善伴左心室收缩功能不全的CTO患者左心室收缩功能,改善左心室重构。  相似文献   

12.
目的探讨沙库巴曲缬沙坦(sacubitril valsartan)在急性心肌梗死(acute myocardial infarction,AMI)患者经皮冠状动脉介入(percutaneous coronary intervention,PCI)治疗后的临床疗效及近期预后。方法选取上海市奉贤区中心医院2018年1月至2019年1月因AMI入院并行PCI治疗的123例患者作为研究对象,依据术后药物的治疗方式分为对照组(n=67,口服依那普利)和干预组(n=56,口服沙库巴曲缬沙坦),比较两组患者治疗前和治疗后超声心动图指标、血管内皮损伤及炎症反应等相关指标、N末端B型脑钠肽前体(N-terminal B-type natriuretic peptide,NT-proBNP)、6 min步行试验(6-minute walk test,6MWT)、明尼苏达心力衰竭患者生活质量问卷(Minnesota living heart failure questionnaire,MLHFQ)评分。结果两组患者治疗前左心室舒张末期内径(left ventricular end diastolic diameter,LVEDD)、左心室收缩末期内径(left ventricular end systolic diameter,LVESD)、左心室射血分数(left ventricular ejection fraction,LVEF)、内皮素-1(endothelin-1,ET-1)、一氧化氮(nitric oxide,NO)、血清肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-6(interleukin-6,IL-6)、NT-proBNP、6MWT及MLHFQ比较,差异无统计学意义(P>0.05)。治疗后,干预组患者的LVEDD、LVESD、ET-1、NT-proBNP、IL-6、TNF-α低于对照组,LVEF、NO、6MWT高于对照组,MLHFQ评分低于对照组,差异有统计学意义(P<0.05)。干预组患者主要心脑血管不良事件(MACCE)发生率、心血管不良事件再入院率和药物不良反应率低于对照组,差异有统计学意义(P<0.05)。讨论沙库巴曲缬沙坦可改善AMI患者PCI治疗后的心室重构,降低炎症反应,提高运动耐量,改善患者的近期预后及生存质量。  相似文献   

13.
Tomaszuk-Kazberuk A  Musiał WJ  Dobrzycki S  Korecki J 《Kardiologia polska》2004,60(6):541-9; discussion 550-1
BACKGROUND: It has been shown that normalisation of elevated ST segment after primary percutaneous coronary interventions (PCI) is associated with the achievement of reperfusion at the tissue level. AIM: To assess prospectively the return of left ventricular (LV) systolic function and the outcome of patients with acute myocardial infarction (AMI), treated with primary PCI, in relation to the early normalisation of the ST segment. METHODS: The study group consisted of 110 consecutive patients (33 females, 77 males, mean age 56 years) with AMI who were successfully treated with primary PCI (TIMI flow grade 3 and residual stenosis <30%) within 12 hours from the onset of symptoms. The patients were divided into two groups according to normalisation or lack of normalisation of an elevated ST segment. The mean time from the onset of symptoms to the restoration of blood flow in an infarct-related artery (pain-to-balloon time) was similar in both groups. LV echocardiographic parameters (ejection fraction EF and wall motion score index WMSI) and clinical status directly after PCI as well as 3 and 6 months later were assessed. RESULTS: Directly after primary PCI, LV impairment (low EF and high WMSI) was significantly more often present in patients without rather than with ST segment normalisation. Afterwards, LVEF and WMSI improved significantly only in patients with ST segment normalisation whereas in the remaining patients no such improvement was observed. During 6-month follow-up period, major cardiac events (death, new AMI or need for revascularisation) occurred more frequently in patients without rather than with ST segment normalisation (p=0.03). CONCLUSIONS: 1. Rapid resolution of ST segment elevation following effective primary PCI identifies patients with a favourable outcome. 2. ST segment normalisation predicts a return of LV systolic function in patients with AMI treated with primary PCI.  相似文献   

14.
目的:探讨急性心肌梗死(AMI)后行急诊经皮冠状动脉成形术(PCI)和行择期PCI治疗的近期疗效和安全性。方法:248例AMI患者被分为两组,急诊PCI组19例,择期PCI组229例。对两组患者住院期间用药情况及PCI后心功能进行分析。结果:两组患者术后心功能各项指标均明显改善,与择期PCI组相比,急诊PCI组左室射血分数明显提高[(52.7±6.3)%比(54.1±2.7)%],左室舒张末内径明显减小[(48.8±1.7)mm比(47.8±2.4)mm],P均〈0.05。结论:急性心肌梗死后行急诊经皮冠状动脉成形术是一种安全有效的介入性治疗手段,可以防止再梗死和心肌缺血,进一步改善心功能。  相似文献   

15.
目的 评估ZEEK血栓抽吸导管在老年人急性心肌梗死患者治疗中的应用.方法 将94例行急诊介入治疗的老年急性ST抬高心肌梗死患者分为两组,其中使用ZEEK血栓抽吸导管52例(抽吸组),未使用ZEEK血栓抽吸导管42例(对照组).观察无复流发生率、术后ST段下降率、住院病死率及左心室射血分数等.结果 ZEEK组1例(1.9%)发生无复流,住院期间无死亡;对照组中5例(11.9%)发生无复流,死亡2例(4.8%).两组患者的无复流发生率、ST段下降率、住院病死率及心功能差异有统计学意义(均P<0.05).结论 老年人急性心肌梗死在急诊介入治疗中,应用ZEEK血栓抽吸导管安全可行,可清除冠状动脉内血栓,改善心肌组织灌注,有可能改善术后心脏功能.  相似文献   

16.
目的:探讨急性心肌梗死(AMI)患者经皮冠脉介入术(PCI)后TIMI血流III级时的心肌灌注水平及其对心功能与左室重构的影响。方法: 对36例AMI患者PCI后行经静脉心肌声学造影(MCE)和心脏二维超声检查。①利用心肌声学造影评分(MCS)及室壁运动评分(WMS)分析PCI后心肌灌注情况与室壁运动情况的关系;②根据声学造影积分指数(CSI)将患者分为A、B两组,比较两组的左室射血分数(LVEF),评估心肌灌注水平对心功能的影响;③根据心脏二维超声结果,比较两组患者术后6个月时左室舒张末直径(LVEDD)及LVEF的变化,进一步评估心肌灌注水平对左室重构的影响。结果: PCI后梗死相关血管TIMI血流均达III级。共152节段与梗死相关血管的再灌注有关。①MCS为0分的18节段中,2个(11.1%)WMS为1~2分;MCS为0.5分的30节段中16个(53.3 %)WMS为1~2分;MCS为1分的104节段中,82个(78.8%)WMS为1~2分;统计学分析显示,PCI后心肌灌注水平与室壁运动呈正相关(P<0.05)。②心肌灌注好的A组LVEF显著大于B组[(52.1±3.4)%,(47.2±2.9)%,P<0.05]。③术后6个月A组的LVEF及LVEDD均无明显变化,B组的LVEF较前有所下降[(47.2±2.9)%,(43.8±4.4)%,P<0.05],LVEDD较前有所增加[(50.2±2.9) mm,(56.3±3.1) mm,P<0.05]。结论: AMI患者PCI后心肌灌注水平与心功能及左室重构有一定相关性,良好的心肌灌注在一定程度上可以抑制左室重构。  相似文献   

17.
AIMS: It has been suggested that obstructive sleep apnoea syndrome (OSA) may be a direct cause of left ventricular (LV) systolic dysfunction. This study was designed to examine our hypothesis that OSA inhibits the recovery of LV function in patients with acute myocardial infarction (AMI). METHODS AND RESULTS: Our 86 consecutive first-AMI patients underwent primary percutaneous coronary intervention (PCI). All patients underwent polysomnography and OSA was defined as an apnoea-hypoapnoea index (AHI) > or =15 events/h, of which more than 50% were obstructive. Left ventriculograms immediately after PCI and at 21 days were used to evaluate LV ejection fraction (LVEF), LV end-diastolic volume index, and regional wall motion (RWM) within the infarct area. OSA was observed in 37 patients (43%). All three indices of LV function after primary PCI were comparable between the two groups. Increases in LVEF and RWM during admission were significantly lower in OSA patients than those without OSA (delta LVEF: -0.3+/-9.6 vs. 7.4+/-7.2%, P < 0.001; delta RWM: 0.26+/-1.04 SD/chord vs. 1.16+/-1.20 SD/chord, P = 0.002). Multiple regression analysis showed that AHI correlated negatively with delta LVEF and delta RWM. CONCLUSION: The novel finding is that OSA may inhibit the recovery of LV function in patients with AMI.  相似文献   

18.
BACKGROUND: The aim of the present study was to investigate the relationship between plasma concentrations of endothelin (ET)-1 and clinical outcome (including mortality) and left ventricular (LV) systolic function in acute myocardial infarction (AMI). METHODS AND RESULTS: The study group comprised 110 consecutive first-AMI patients who were successfully reperfused by primary coronary intervention. Plasma ET-1 concentrations were evaluated 24 h from onset and the patients were divided into 2 groups according to the median value, either a high group (H group: > or = 2.90 pg/ml plasma ET-1; n = 55) or low group (L group: < 2.90 pg/ml plasma ET-1; n = 55). Major complications and LV systolic function were monitored in the 2 groups. Both highly sensitive C-reactive protein (hs-CRP) and brain natriuretic peptide (BNP) showed a significant positive correlation with ET-1 (BNP: r = 048, p < 0.0001, hs-CRP: r = 0.43, p < 0.001). Chronic stage left ventricular ejection fraction (LVEF) and left ventricular end-diastolic volume index (LVEDVI) were significantly poorer in the H group (LVEF: 51+/-15% vs 60+/-13%, p = 0.003, LVEDVI: 74+/-19 ml/m2 vs 66+/-14 ml/m2, p < 0.05). There were significantly more major complications in the H group than in the L group (cardiogenic shock: 18% vs 5%, p = 0.04; cardiac death: 13% vs 0%, p < 0.01). CONCLUSIONS: In the setting of AMI, plasma ET-1 concentrations may be closely related to LV systolic dysfunction and poor patient outcome, including mortality.  相似文献   

19.
目的观察延迟经皮冠状动脉支架植入术(PCI)对急性心肌梗死患者左心室重构及心脏事件的影响。方法将经药物治疗后病情稳定的急性心肌梗死患者分成延迟PCI治疗+药物治疗组(A组)和单纯药物治疗组(B组)。在入院即刻、7d和180d采用超声心动描记术评价左心室整体功能,并进行比较。结果A组患者行PCI术后180d左心室射血分数(LVEF)及左心室舒张末期内径(LVESd)、左心室收缩末期内径(LVESd)等指标(58.49±6.65、45.20±5.15、32.04±8.55)与术后7d(51.69±5.00、47.77±3.10、37.57±5.92)相比,差异有统计学意义(P〈O.05),与B组术后180d(53.16±5.92、46.20±4.60、35.40±7.40)比较,差异均有统计学意义(均P〈0.05);PCI术后7d两组上述指标比较,差异无统计学意义(均P〉0.05)。讨论延迟PCI有助于防止左心室重构.改善心功能,使心脏不良事件明显下降。  相似文献   

20.
不同面积心肌梗死患者心功能减低及预后分析   总被引:1,自引:0,他引:1  
目的探讨不同面积心肌梗死患者的心功能变化及生存预后。方法在有住院资料的896例心肌梗死患者中,选取左室扩大、射血数下降、进行冠状动脉造影但未行冠状动脉介入治疗的患者65例,记录此部分患者心肌梗死后射血分数(LVEF)和左室舒张末内径(LVEDD)的变化情况,使用Kaplan-Meier生存曲线分析患者生存预后情况。结果大面积心肌梗死患者的初始LVEF和LVEDD即比较低,随访期间变化不明显;小面积心肌梗死患者LVEF和LVEDD初始高于大面积心肌梗死患者,但在2~4年随访中期显著下降;多次心肌梗死患者LVEF和LVEDD随时间延长明显降低。Kaplan-Meier生存分析显示,大面积心肌梗死组、小面积心肌梗死组和多次心肌梗死组四年全因死亡率无显著差别(P=0.77);多次心肌梗死组患者四年生存率仅有52,且死亡率随着时间的延长有增加趋势;小面积心肌梗死组患者在2~3年随访中期时间生存率高于大面积心肌梗死组患者,但无统计学意义,随着时间的延长二者死亡率有接近的趋势。结论大面积心肌梗死患者的心功能显著降低,随时间变化不明显;小面积心肌梗死患者心功能初始接近正常,在2~4年间显著下降;多次心肌梗死患者心功能随时间显著降低。大面积、小面积及多次心肌梗死患者四年全因死亡率相近。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号